Answer: Cholangiocarcinoma is a rare cancer that develops from the bile ducts, which are slender tubes that carry the digestive fluid bile and connect the liver to the gallbladder and small intestine.

A new study from researchers at The University of Texas MD Anderson Cancer Center demonstrates that a specialized high-dose ...

Lirafugratinib, an oral FGFR2 inhibitor, receives FDA Priority Review for advanced cholangiocarcinoma with FGFR2 ...

Please provide your email address to receive an email when new articles are posted on . Researchers observed a temporal association between cholangioscopy volume and subsequent cholangiocarcinoma ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Yeah, I think in terms of research ...

Cholangiocarcinoma is a relatively rare adenocarcinoma of the bile ducts that is rapidly fatal unless it can be completely resected. In most cases, the tumor is too advanced for resection by the time ...

With Priority Review designation, FDA set a Sept. 27 PDUFA date for approval decisionLirafugratinib achieved a 46.5% ORR, in CCA patients with ...

Towle was first diagnosed with bile duct cancer at 23 ...

I was initially told it was ‘just acid reflux’.

In October of 2005, my brother, Mark, was diagnosed with cholangiocarcinoma, a rare and aggressive cancer of the bile duct, at the age of 38. This set me on a path of relentless research and advocacy.

A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy. Background: The use of antibody therapy targeting immune ...